AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 35 min read$RVTY

Revvity Shares Jump Nearly 6% as Q3 Earnings Beat Forecasts and 2026 Guidance Improves

Revvity (RVTY) shares rose 5.55% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.37 vs. $1.30 expected. Revenue grew 4% YoY to $729M, surpassing forecasts. Pro forma revenue, excluding China Immunodiagnostics, increased 7% to $710M. Life Sciences revenue grew 10.8% to $380M, while Diagnostics saw a 2% reported decline but 4% pro forma growth.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 2:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 3:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Revvity Shares Jump Nearly 6% as Q3 Earnings Beat Forecasts and 2026 Guidance Improves — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$RVTYBullishHigh
01

Why it matters

The article provides a same-session earnings beat and a quantified guidance raise for 2026 pro forma EPS and revenue, which can drive immediate repricing and momentum trading.

02

Market read

Guidance increases tied to pro forma metrics are likely to be the dominant catalyst for RVTY positioning into the next trading sessions.

03

What to watch

Traders should separate reported vs pro forma results and monitor whether the organic growth rate decelerates versus the prior quarter’s 7% pro forma organic increase.

Relevance 9/10Novelty 9/10Timing: premarket Tuesday after the Q3 print and guidance raise

Background

Revvity is a health sciences technology company reporting both reported and pro forma results that exclude a China Immunodiagnostics business pending divestiture.

Company-level read

Ticker impact

$RVTYBullishHigh confidence
Context

Revvity reported Q3 adjusted EPS of $1.37 vs $1.30 consensus and raised full-year 2026 pro forma EPS to $5.40-$5.45.

Expected impact

Likely upward pressure as traders reprice 2026 earnings expectations and the market digests the pro forma guidance framework.

Evidence & confidence

The article discloses both a quantified earnings/revenue beat and a specific guidance increase, which are direct drivers of valuation and positioning.

Market effects

Sector

Supports sentiment for health sciences tools and diagnostics demand, with Life Sciences growth cited as the key driver.

Regional

Primarily US-listed large-cap sentiment; limited direct regional spillover beyond biotech/health-tech complex.

Global

China Immunodiagnostics divestiture framing may affect how investors model international diagnostics exposure.

Counterpoint

What could challenge this read

The Diagnostics segment showed reported revenue decline, so the upside may be partly accounting-driven by the pending China Immunodiagnostics divestiture.

Key entities

  • company
    Revvity, Inc.

    Reported Q3 2026 adjusted EPS and revenue beat, raised full-year 2026 pro forma guidance, and highlighted Life Sciences growth.

  • business_unit
    China Immunodiagnostics business

    Pending divestiture that is excluded from pro forma reporting, affecting segment and consolidated comparisons.

Read at source← All news

StoryRevvity beats Q3 expectations and raises 2026 guidance

Also covered by

4 outlets

Related articles

NOV 3
$RVTYMed

Revvity, Inc. Q3 2026 Earnings Call Summary

Revvity, Inc. reported Q3 2026 earnings, highlighting a 9% organic growth in Life Sciences, driven by reagent and software demand. Management raised full-year guidance to 5% growth, citing AI-related demand and operational efficiencies. The company expects sustainable margins and plans to divest its China immunodiagnostics business in 2027. Key growth areas include reagents and Signals software, with AI-native offerings launching in 2026.

finance.yahoo.com7 min
NOV 3
$RVTYHighAI 8/10

Revvity Q3 2026 slides: strong growth, margin expansion lift outlook

Revvity reported Q3 2026 revenue of $710M, up 7% YoY, with adjusted operating margins expanding to 29.4%. EPS grew 21% to $1.37. The company raised full-year guidance, citing strong demand and operational improvements. Life Sciences and Diagnostics segments showed growth, with the Americas and Europe outperforming Asia-Pacific. Revvity's stock surged 8.85% premarket to $165.01.

investing.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Shares Jump After Strong Q3, Raises Outlook

Revvity shares rose 8.8% premarket after Q3 2026 earnings beat expectations, with adjusted EPS at $1.37 and revenue at $729M. The company raised FY 2026 guidance, targeting $5.40–$5.45 EPS and $2.86B revenue. Life Sciences segment grew 11%, and operating margin improved to 13.1%. CEO attributed results to strong execution. TD Cowen raised its price target to $175 in October.

tradingpedia.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Announces Financial Results for the Third Quarter of 2026

REVVITY, INC. (RVTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE November 3, 2026 Revvity Announces Financial Results for the Third Quarter of 2026 • Revenue of $729 million; pro forma revenue of $710 million; 7% pro forma revenue growth; 7% pro forma organic revenue growth • GAAP EPS from continuing operations of $0.56 ;

SEC EDGAR 8-K2 min
NOV 3
$RVTYHighAI 8/10

Why is Revvity stock surging today?

Revvity (RVTY) stock rose 8.8% in pre-market trading after its Q3 2026 earnings beat estimates, with adjusted EPS of $1.37 and revenue of $729M. The company raised its full-year guidance, citing strong segment growth and margin expansion. CEO Prahlad Singh highlighted broad-based growth. The move was driven by company-specific news, not broader market trends. TD Cowen had previously raised its price target to $175.

investing.com2 min